Roivant Sciences Ltd.
ROIV
$11.92
$0.110.93%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -223.36M | -206.48M | 169.38M | -- | 95.30M |
| Total Depreciation and Amortization | 1.10M | 8.16M | 1.94M | -- | 2.05M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 54.97M | -8.74M | -325.47M | -- | -209.17M |
| Change in Net Operating Assets | -37.10M | 34.48M | -53.11M | -- | -81.00M |
| Cash from Operations | -204.38M | -172.57M | -207.25M | -- | -192.83M |
| Capital Expenditure | -4.04M | -811.00K | -1.83M | -- | -965.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | 74.93M | 154.44M | -- | -- |
| Other Investing Activities | -1.08B | 1.00B | 301.46M | -- | -- |
| Cash from Investing | -1.09B | 1.07B | 454.07M | -- | -965.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 0.00 | -49.09M | -- | -1.83M |
| Issuance of Common Stock | 30.06M | 12.97M | 28.12M | -- | 2.27M |
| Repurchase of Common Stock | -217.83M | -302.91M | -251.98M | -- | -661.06M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 112.78M | -- | -- | -- |
| Cash from Financing | -187.77M | -177.15M | -272.95M | -- | -660.62M |
| Foreign Exchange rate Adjustments | 815.00K | -489.00K | -1.07M | -- | -2.74M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.48B | 723.99M | -27.20M | -- | -857.15M |